Mediar Therapeutics
New perspective. Novel targets. Clinical trials.
$76M Series B+ ·
Led by Amplitude Venture Capital · Source: fundraisingfox.com
Total raised: $181M across 2 sourced rounds
All 2 rounds ↓Signals
Website registeredDec 6, 2018 (7 years old)
About Mediar Therapeutics
The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in organ systems. By deactivating the myofibroblast, we hope to slow fibrosis and possibly reverse it.
Funding rounds
- Series B+ · $76M
AAmplitude Venture Capital (lead),
IIntermediate Capital Group (lead),
AAlexandria Real Estate Equities,
AAsahi Kasei Pharma,
LLongwood Fund
Source: fundraisingfox.com - Series A · $105M
NNovartis Venture Fund (lead),
SSofinnova Partners (lead),
BBristol-Myers Squibb,
EEli Lilly & Company Foundation,
GGimv,
MMass General Brigham Ventures,
MMission BioCapital,
OOno Venture Investment,
PPfizer Venture Investments,
PPureos Bioventures
Source: mediartx.com - Website created
Founders and team
DL
David Lagares FounderMF
Meredith Fisher FounderPY
Paul Yaworsky FounderRB
Rahul Ballal CEOJB
Jeffrey Bornstein Chief Medical Officer- SSSimon Sturge Executive chairman
Investors
Companies like Mediar Therapeutics
MMelodi Health$10.75M Series A · Sep 2024GGranite Bio$30M Series A · Apr 2025
CCelea Therapeutics$180M Series A · Jul 2026
AActio Biosciences$66M Series B+ · Jun 2025
IImmunai$215M Series B+ · Oct 2021
AArray Labs$20M Series A · Jan 2026
Other companies backed by Amplitude Venture Capital
FFluid Biomed$27M Series A · Dec 2024
TTentarixSeries B+ · Sep 2023
Amplitude Venture Capital portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/mediar-therapeutics (get a free API key).